ANTIANGIOGENIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY

• DOI: 10.1097/iae.0b013e318159ec6b
• Publication Date: 2009-03-05T16:06:56Z
• Authors: HUGO QUIROZ-MERCADO; MARIA A. MARTINEZ...; MYRIAM L. HERNAND...; NELIDA SALAZAR-TERAN; ROBINSON VERNON P...
• Keywords: Male; Infant, Newborn; Antibodies, Monoclonal; Infant; Angiogenesis Inhibitors; Infant, Low Birth Weight; Antibodies, Monoclonal, Humanized; Injections; 3. Good health; Bevacizumab; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Humans; Female; Retinopathy of Prematurity; Prospective Studies; Infant, Premature

In Brief Purpose: To evaluate the role of antiangiogenic therapy with intravitreal bevacizumab for retinopathy prematurity (ROP). Methods: this noncomparative, prospective, interventional case series, was injected into vitreous patients ROP in three different groups: group I, stage IVa or IVb who had no response to conventional treatment; II, threshold were difficult treat because poor visualization retina; and III, high-risk prethreshold ROP. Results: Thirteen (18 eyes; mean age ± SD, 4 3 months; follow-up, 6 months) included study. We found neovascular regression 17 eyes. One patient spontaneous retinal reattachment after an injection bevacizumab. There serious ocular systemic adverse events. Conclusion: The use may be promising treatment Further studies need performed determine safety long-term efficacy bevacizumab, either as first-line failure therapy. prematurity.